Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer - Related Studies

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

This study has been completed.

Study NCT00003382. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Fallopian Tube Cancer
		Ovarian Cancer
		Peritoneal Cavity Cancer

2	Additional conditions recognized in this trial
		Fallopian Tube Neoplasms
		Ovarian Neoplasms

3	More general conditions related to this trial
		Adnexal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Fallopian Tube Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Neoplasms
		Neoplasms by Site
		Ovarian Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		filgrastim
		gemcitabine hydrochloride
		topotecan hydrochloride

5	Additional drug interventions recognized in this trial
		Gemcitabine
		Topotecan

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Gynecologic Oncology Group
		National Cancer Institute (NCI)